The 340B Program and oral specialty drugs for advanced prostate cancer.
Kassem S FarajSamuel R KaufmanMary OerlineLindsey A HerrelAvinash MagantyMegan E V CaramVahakn B ShahinianBrent K HollenbeckPublished in: Cancer (2024)
The 340B program was not associated with specialty drug use in men with advanced prostate cancer. However, among those who were started on therapy, 340B was associated with increased treatment adherence in more socially vulnerable men.